Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line ...
MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung cancer (ES-SCLC). The primary objective is the safety evaluation. ...
49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)doi:10.1093/annonc/mdy486Califano, RKażarnowicz, AKaraseva, N...
Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS ...
Atezolizumab plus carboplatin and etoposide therapy was effective in SCLC patients with sensitive and refractory relapse and might be a second-line treatment option for SCLC patients previously treated with platinum-based chemotherapy.doi:10.1007/s10637-020-00983-6Ishii, Hidenobu...
The patients were divided into two groups: The 1st group comprised 14 (41.2%) individuals who received four 21-day cycles of carboplatin (AUC 5 mg/mL/min intravenously on day 1) + etoposide (100 mg/m intravenously on days 1-3) + atezolizumab (1200 mg intravenously on day 1). ...
We present a real-world analysis, conducted in a Spanish tertiary hospital, that assesses the efficacy and safety of Atezolizumab combined to Carboplatin-Etoposide (Atezo-CE) in first-line ES-SCLC treatment, based on the Impower-133 Clinical Trial (CT).Methods:In this longitudinal, retrospective ...
This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteCE). This retrospective study evaluated patients with relapsed SCLC who were treated with ...
58TiPIMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLCMolecular Biology of Lung Cancerdoi:10.1093/annonc/mdx088.008Reck, M.Mansfield, A.S.Liu, S.V.Mok, T.S.K.Tang, X.Lam, S.Kabbinavar, F....
Atezolizumab, carboplatin, andetoposide (ACE) therapy is a standard of care for extensive-disease small cell lung cancer(SCLC); however, its safety data are scarce, limiting generalization to the Japanese population.#This study aimed to compare the safety of ACE versus carboplatin and etoposide (...